🔊Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL
🎧 buff.ly/9NpzqEQ #hemesky #podcast #lymphoma
🎧 buff.ly/9NpzqEQ #hemesky #podcast #lymphoma
April 4, 2025 at 12:00 PM
🔊Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL
🎧 buff.ly/9NpzqEQ #hemesky #podcast #lymphoma
🎧 buff.ly/9NpzqEQ #hemesky #podcast #lymphoma
🎙️ Just published a new episode of Blood Podcast: Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL. Have a listen:
Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL
In this week's episode tracking the functional profile of aging...
share.transistor.fm
April 3, 2025 at 3:53 PM
🎙️ Just published a new episode of Blood Podcast: Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL. Have a listen:
The phase 2 ELM-2 trial shows odronextamab, a CD20×CD3 bispecific antibody, delivers 52% ORR and 31.5% CRs in heavily pretreated relapsed/refractory DLBCL.
@naturecancer.bsky.social @lymphomaaction.bsky.social @lymphomacommunity.bsky.social
#Onco404 #Cancer #Hematology #DLBCL #ClinicalTrials
@naturecancer.bsky.social @lymphomaaction.bsky.social @lymphomacommunity.bsky.social
#Onco404 #Cancer #Hematology #DLBCL #ClinicalTrials
April 7, 2025 at 10:01 AM
The phase 2 ELM-2 trial shows odronextamab, a CD20×CD3 bispecific antibody, delivers 52% ORR and 31.5% CRs in heavily pretreated relapsed/refractory DLBCL.
@naturecancer.bsky.social @lymphomaaction.bsky.social @lymphomacommunity.bsky.social
#Onco404 #Cancer #Hematology #DLBCL #ClinicalTrials
@naturecancer.bsky.social @lymphomaaction.bsky.social @lymphomacommunity.bsky.social
#Onco404 #Cancer #Hematology #DLBCL #ClinicalTrials
Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma www.tandfonline.com/doi/10.1080/... #hvhebron #hemat [Text complet] @tandfresearch.bsky.social
Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma
To contextualize results from the single-arm ELM-2 study of odronextamab (CD20 × CD3 bispecific antibody) in relapsed/refractory (R/R) follicular lymphoma (FL) (N = 128), a post-hoc comparison was ...
www.tandfonline.com
March 4, 2026 at 3:55 PM
Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma www.tandfonline.com/doi/10.1080/... #hvhebron #hemat [Text complet] @tandfresearch.bsky.social
Epcoritamab also showed clinically relevant, numerically higher ORRs and improved safety vs mosunetuzumab or odronextamab. buff.ly/e3qt3Tp #hemesky
August 15, 2025 at 3:03 PM
Epcoritamab also showed clinically relevant, numerically higher ORRs and improved safety vs mosunetuzumab or odronextamab. buff.ly/e3qt3Tp #hemesky
🚨Check out this phase 2 clinical trial of odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma published at @naturecancer.bsky.social by Won Seog Kim and colleagues:
www.nature.com/articles/s43...
www.nature.com/articles/s43...
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial - Nature Cancer
Kim and colleagues perform a phase 2 clinical trial (ELM-2) of odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma and report on the primary analyses of the eff...
www.nature.com
April 7, 2025 at 12:29 PM
🚨Check out this phase 2 clinical trial of odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma published at @naturecancer.bsky.social by Won Seog Kim and colleagues:
www.nature.com/articles/s43...
www.nature.com/articles/s43...
📣ESMO #ClinicalPracticeGuideline on #Lymphomas - New Living Guideline recommendations in the relapsed/refractory setting:
- Epcoritamab combinations and odronextamab in Follicular Lymphoma
- Sonrotoclax in Mantle Cell Lymphoma thrid-line or later
🔗 https://ow.ly/v7Uo50YcbSE
- Epcoritamab combinations and odronextamab in Follicular Lymphoma
- Sonrotoclax in Mantle Cell Lymphoma thrid-line or later
🔗 https://ow.ly/v7Uo50YcbSE
February 11, 2026 at 9:50 AM
📣ESMO #ClinicalPracticeGuideline on #Lymphomas - New Living Guideline recommendations in the relapsed/refractory setting:
- Epcoritamab combinations and odronextamab in Follicular Lymphoma
- Sonrotoclax in Mantle Cell Lymphoma thrid-line or later
🔗 https://ow.ly/v7Uo50YcbSE
- Epcoritamab combinations and odronextamab in Follicular Lymphoma
- Sonrotoclax in Mantle Cell Lymphoma thrid-line or later
🔗 https://ow.ly/v7Uo50YcbSE
Odronextamab post-CAR #ASH24 @DrMatasar:
- 60 pts, med 6.5 mos post CAR, 48% R/R w/i 90d
- ORR 48%, CR 32% (ORR 21% if R/R w/i 90d)
- mPFS 4.8 mos, OS 10.2 mos
- CRS all G1-2, no ICANS, 20% G3 infx
Outcomes poor, especially in early relapse post-CAR setting (unmet need). #lymsm
- 60 pts, med 6.5 mos post CAR, 48% R/R w/i 90d
- ORR 48%, CR 32% (ORR 21% if R/R w/i 90d)
- mPFS 4.8 mos, OS 10.2 mos
- CRS all G1-2, no ICANS, 20% G3 infx
Outcomes poor, especially in early relapse post-CAR setting (unmet need). #lymsm
November 14, 2024 at 8:37 PM
We spoke with Matthew Matasar, MD, of Rutgers Cancer Institute, at @ash-hematology.bsky.social #ASH24 about the primary analysis of the ELM-1 study on the efficacy and safety of #odronextamab monotherapy in #DLBCL progressing after CAR T-cell therapy. Check back on www.onclive.com/conference/ash
December 9, 2024 at 12:04 AM
We spoke with Matthew Matasar, MD, of Rutgers Cancer Institute, at @ash-hematology.bsky.social #ASH24 about the primary analysis of the ELM-1 study on the efficacy and safety of #odronextamab monotherapy in #DLBCL progressing after CAR T-cell therapy. Check back on www.onclive.com/conference/ash
✅ MRD clearance at Cycle 4 Day 15 linked to longer progression-free survival.
🌍 This off-the-shelf therapy offers hope for patients with limited options post-CAR T or multi-line failure. With phase 3 trials underway, odronextamab could impact the R/R DLBCL landscape!
#Onco404
🌍 This off-the-shelf therapy offers hope for patients with limited options post-CAR T or multi-line failure. With phase 3 trials underway, odronextamab could impact the R/R DLBCL landscape!
#Onco404
April 7, 2025 at 10:01 AM
✅ MRD clearance at Cycle 4 Day 15 linked to longer progression-free survival.
🌍 This off-the-shelf therapy offers hope for patients with limited options post-CAR T or multi-line failure. With phase 3 trials underway, odronextamab could impact the R/R DLBCL landscape!
#Onco404
🌍 This off-the-shelf therapy offers hope for patients with limited options post-CAR T or multi-line failure. With phase 3 trials underway, odronextamab could impact the R/R DLBCL landscape!
#Onco404
Odronextamab in rare B-NHLs @BachyEmmanuel:
- 46 pts in ELM-2 'other' cohort: HGBL, PMBL, FL3B, BL, EBV+, DHL, THRLBCL
- ORR 61%, CR 44%, 3-yr DOR 54%
- 5 d/c'd d/t TEAEs; 1 G3 CRS, no ICANS; 39% G3 infx, 2 G5 infx
Looking forward to responses by NHL subtype at #ASH24. #lymsm
- 46 pts in ELM-2 'other' cohort: HGBL, PMBL, FL3B, BL, EBV+, DHL, THRLBCL
- ORR 61%, CR 44%, 3-yr DOR 54%
- 5 d/c'd d/t TEAEs; 1 G3 CRS, no ICANS; 39% G3 infx, 2 G5 infx
Looking forward to responses by NHL subtype at #ASH24. #lymsm
November 14, 2024 at 3:42 PM
Regeneron got another FDA rejection for odronextamab and expects delays for Eylea HD. Regeneron also forecasts pending PDUFAs for Eylea HD could be delayed.
Regeneron gets another CRL, predicts delayed August PDUFA for Eylea HD
Regeneron's bispecific antibody has been rejected for the second time, and the drugmaker expects delays to other pending FDA approvals for Eylea HD, it said during a second-quarter earnings announceme...
endpoints.news
August 1, 2025 at 3:42 PM
Regeneron got another FDA rejection for odronextamab and expects delays for Eylea HD. Regeneron also forecasts pending PDUFAs for Eylea HD could be delayed.
Une nouvelle #Immunothérapie qui donne de l’espoir aux patients atteint de #CancerDuSang 🩸 agressif, le #Lymphome diffus à grandes cellules B
Une nouvelle molécule, l’ #Odronextamab, un #AnticorpsBispécifique 💊 apporte de l’espoir dans l'étude #Olympia_3
www.medisite.fr/actualites-c...
Une nouvelle molécule, l’ #Odronextamab, un #AnticorpsBispécifique 💊 apporte de l’espoir dans l'étude #Olympia_3
www.medisite.fr/actualites-c...
Cancer du sang : un nouveau traitement suscite l’espoir pour cette maladie encore trop mortelle
Au congrès mondial de la société américaine d’hématologie, les chercheurs de Gustave Roussy dévoilent des avancées majeures contre les cancers du sang, dont un traitement montrant des résultats promet...
www.medisite.fr
January 14, 2026 at 3:53 PM
Une nouvelle #Immunothérapie qui donne de l’espoir aux patients atteint de #CancerDuSang 🩸 agressif, le #Lymphome diffus à grandes cellules B
Une nouvelle molécule, l’ #Odronextamab, un #AnticorpsBispécifique 💊 apporte de l’espoir dans l'étude #Olympia_3
www.medisite.fr/actualites-c...
Une nouvelle molécule, l’ #Odronextamab, un #AnticorpsBispécifique 💊 apporte de l’espoir dans l'étude #Olympia_3
www.medisite.fr/actualites-c...
Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Making sure you're not a bot!
scientiasalut.gencat.cat
August 21, 2026 at 10:55 AM
Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Comparative effectiveness of odronextamab (CD20 × CD3 bispecific antibody) versus real-world systemic therapies in relapsed/refractory follicular #lymphoma
Alt text: follow link to abstract
pubmed.ncbi.nlm.nih.gov/41736495/
Alt text: follow link to abstract
pubmed.ncbi.nlm.nih.gov/41736495/
March 2, 2026 at 9:07 AM
Comparative effectiveness of odronextamab (CD20 × CD3 bispecific antibody) versus real-world systemic therapies in relapsed/refractory follicular #lymphoma
Alt text: follow link to abstract
pubmed.ncbi.nlm.nih.gov/41736495/
Alt text: follow link to abstract
pubmed.ncbi.nlm.nih.gov/41736495/
Health-Related Quality of Life With Odronextamab Monotherapy ( CD20 x CD3 bispecific monoclonal antibody) for Relapsed/Refractory Follicular #Lymphoma in the ELM-2 Study
pubmed.ncbi.nlm.nih.gov/40571446/
#cancer #news #QoL #Medsky
pubmed.ncbi.nlm.nih.gov/40571446/
#cancer #news #QoL #Medsky
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study - PubMed
In this heavily pretreated, highly refractory population, maintenance or improvement of health-related quality of life, functioning, and symptoms support odronextamab as a potential treatment option i...
pubmed.ncbi.nlm.nih.gov
August 27, 2025 at 10:13 AM
Regeneron Most Cancers Bispecific Rejected Once More; Allogene Discloses Trial Loss Of Life
The FDA issued an entire response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its steerage and analysts noticed progress in Biogen’s turnaround. Elevate your…
The FDA issued an entire response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its steerage and analysts noticed progress in Biogen’s turnaround. Elevate your…
Regeneron Most Cancers Bispecific Rejected Once More; Allogene Discloses Trial Loss Of Life
The FDA issued an entire response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its steerage and analysts noticed progress in Biogen’s turnaround. Elevate your perspective with NextTech Information, the place innovation meets perception.Uncover the newest breakthroughs, get unique updates, and join with a world community of future-focused thinkers.Unlock tomorrow’s traits as we speak: learn extra, subscribe to our publication, and grow to be a part of the NextTech neighborhood at NextTech-news.com Stay ahead of the curve with NextBusiness 24. Explore more stories, subscribe to our newsletter, and join our growing community at nextbusiness24.com
nextbusiness24.com
August 2, 2025 at 5:36 AM
Regeneron Most Cancers Bispecific Rejected Once More; Allogene Discloses Trial Loss Of Life
The FDA issued an entire response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its steerage and analysts noticed progress in Biogen’s turnaround. Elevate your…
The FDA issued an entire response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its steerage and analysts noticed progress in Biogen’s turnaround. Elevate your…
Regeneron cancer bispecific rejected again; Allogene discloses trial death
The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround. Elevate your perspective with NextTech…
The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround. Elevate your perspective with NextTech…
Regeneron cancer bispecific rejected again; Allogene discloses trial death
The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround. Elevate your perspective with NextTech News, where innovation meets insight. Discover the latest breakthroughs, get exclusive updates, and connect with a global network of future-focused thinkers. Unlock tomorrow’s trends today: read more, subscribe to our newsletter, and become part of the NextTech community at NextTech-news.com
nexttech-news.com
August 2, 2025 at 5:32 AM
Regeneron cancer bispecific rejected again; Allogene discloses trial death
The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround. Elevate your perspective with NextTech…
The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround. Elevate your perspective with NextTech…
Regeneron's odronextamab faces regulatory challenges in the US after a roller-coaster journey. Stay tuned for updates on the company's lymphoma treatment progress.
December 7, 2025 at 8:02 PM
Regeneron's odronextamab faces regulatory challenges in the US after a roller-coaster journey. Stay tuned for updates on the company's lymphoma treatment progress.
#PublicaSalutIB 🔬🦠Antonio Gutiérrez de Son Espases i IdISBa ha participat en la publicació d'un estudi sobre Odronextamab en limfoma B https://www.infosalut.com/investigacio/estudis-i-projectes/17587 https://doi.org/10.1038/s43018-025-00921-6
July 3, 2025 at 9:29 AM
#PublicaSalutIB 🔬🦠Antonio Gutiérrez de Son Espases i IdISBa ha participat en la publicació d'un estudi sobre Odronextamab en limfoma B https://www.infosalut.com/investigacio/estudis-i-projectes/17587 https://doi.org/10.1038/s43018-025-00921-6
Odronextamab induced complete responses in 73.4% of heavily pretreated relapsed or refractory follicular lymphoma patients, often by first assessment, with remissions lasting beyond 2 years. Responses were also seen in high-risk disease and low CD20 expression 👉https://bit.ly/4sN50IH
June 1, 2026 at 10:02 AM
Odronextamab induced complete responses in 73.4% of heavily pretreated relapsed or refractory follicular lymphoma patients, often by first assessment, with remissions lasting beyond 2 years. Responses were also seen in high-risk disease and low CD20 expression 👉https://bit.ly/4sN50IH
ELM-1 cohort study assesses odronextamab after #CAR-T therapy for #DLBCL
sohoinsider.com/lymphoma/agg...
sohoinsider.com/lymphoma/agg...
Odronextamab yields 48.3% response in DLBCL
Odronextamab yields 48.3% response in DLBCL after CAR-T failure, per ELM-1 study, offering hope for relapsed patients
sohoinsider.com
April 16, 2025 at 9:07 PM
ELM-1 cohort study assesses odronextamab after #CAR-T therapy for #DLBCL
sohoinsider.com/lymphoma/agg...
sohoinsider.com/lymphoma/agg...
FDA accepts review for odronextamab BLA in r/r follicular lymphoma
https://cancerletter.com/drugs-and-targets/20250228_11a/
https://cancerletter.com/drugs-and-targets/20250228_11a/
FDA accepts review for odronextamab BLA in r/r follicular lymphoma - The Cancer Letter
FDA accepted for review the resubmission of the Regeneron Pharmaceuticals, Inc.’s Biologics License Application for Ordspono (odronextamab) in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy. The target action date for the FDA decision is July 30. To access this subscriber-only content please log in or subscribe.If your institution has a site […]
cancerletter.com
March 3, 2025 at 8:00 PM
FDA accepts review for odronextamab BLA in r/r follicular lymphoma
https://cancerletter.com/drugs-and-targets/20250228_11a/
https://cancerletter.com/drugs-and-targets/20250228_11a/